PARP1 and ovarian carcinoma: Pre-mRNA splicing modulation followed by PARP inhibition or chemotherapy in BRCA-mutant breast and ovarian cancers characterized by a “BRCA-ness” phenotype of dysfunctional homologous DNA repair [48].